Bupropion evaluated for apathy associated with Alzheimer’s disease
This 12-week double-blind clinical trial from Germany compared bupropion 150 mg/day for 4 weeks then 300 mg/day for 8 weeks with placebo in 108 people with mild to moderate Alzheimer’s disease and apathy but not depression.
After adjusting for baseline apathy score (using the Main Outcomes and Measures Change on the Apathy Evaluation Scale; mean baseline scores 50 – 52) and drug treatment, there was no difference between bupropion and placebo after 12 weeks, with a mean overall change of only 2 points. Improvement in total neuropsychiatric symptoms and health-related quality of life was greater with placebo and there were no differences in activities of daily living and cognition scores. The frequency of adverse events was 61% with placebo and 72% with bupropion.